|Mr. Mark Diamond BSc, MBA, MAICD||CEO, MD & Director||N/A||N/A||N/A|
|Mr. Phillip Allen Hains BBus(Acc), MBA, CA||CFO & Company Sec.||N/A||N/A||59|
|Dr. George Tachas||Director of Drug Discovery & Patents||N/A||N/A||N/A|
|Susan Turner||Fin. & Admin. Mang.||N/A||N/A||N/A|
Antisense Therapeutics Limited engages in the research and development of antisense pharmaceuticals in Australia. The companys product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of insulin like growth factor 1 receptor for prostate cancer treatment. Its product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as a potential treatment for diseases associated with excessive growth hormone action. The company is based in Toorak, Australia.
Antisense Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.